University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Not Applicable

Terminated

Conditions: Glaucoma

Interventions: Drug: Ranibizumab

First Posted Date: 2008-03-26

Last Posted Date: 2022-08-02

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 11

Registration Number: NCT00644280

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Behavioral: Cognitive behavioral coping effectiveness training
Behavioral: Standard care
Behavioral: Single group workshop on coping effectiveness training

First Posted Date: 2008-03-26

Last Posted Date: 2023-12-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 250

Registration Number: NCT00643903

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Craving and Lifestyle Management Through Mindfulness Pilot Study

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Craving and Lifestyle Management through Mindfulness(CALMM+)

First Posted Date: 2008-03-26

Last Posted Date: 2014-10-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 15

Registration Number: NCT00643344

Locations: 🇺🇸
UCSF CTSI Clinical Research Center, San Francisco, California, United States

Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers

Phase 2

Completed

Conditions: Cigarette Smoking

Interventions: Behavioral: Self-Help Manual
Behavioral: Mail-based Self-help plus Internet-based Smoking Treatment
Behavioral: Self-Help Manual plus Telephone counseling
Behavioral: Self-Help Manual plus Internet-based Intervention plus Telephone Counseling

First Posted Date: 2008-03-12

Last Posted Date: 2012-06-27

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 363

Registration Number: NCT00634218

Locations: 🇺🇸
Univeristy of California, San Francisco, San Francisco, California, United States

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Phase 2

Terminated

Conditions: Peripheral T-Cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Navelbine
Drug: Doxorubicin Hydrochloride Liposome Injection
Drug: Granulocyte-colony stimulating factor (G-CSF)
Drug: Pegfilgrastim
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Leucovorin
Drug: Methotrexate
Drug: Doxorubicin Hydrochloride
Drug: Cytarabine
Drug: Etoposide
Drug: Carmustine
Drug: Denileukin diftitox

First Posted Date: 2008-03-11

Last Posted Date: 2020-04-27

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 21

Registration Number: NCT00632827

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

Phase 1

Terminated

Conditions: Klatskin Tumor
Cholangiocarcinoma
Biliary Tract Cancer

Interventions: Radiation: External beam radiation and Cyberknife radiosurgery boost and capecitabine

First Posted Date: 2008-03-07

Last Posted Date: 2015-09-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 11

Registration Number: NCT00630890

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Raltegravir Intensification in HIV-infected Patients

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Placebo
Drug: Raltegravir

First Posted Date: 2008-03-07

Last Posted Date: 2020-08-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 30

Registration Number: NCT00631449

Locations: 🇺🇸
San Francisco General Hospital, Clinical Research Center, San Francisco, California, United States
🇺🇸
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

Phase 1

Completed

Conditions: Pancreatic Cancer
Biliary Cancer

Interventions: Drug: gemcitabine
Drug: capecitabine

First Posted Date: 2008-02-29

Last Posted Date: 2012-04-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 45

Registration Number: NCT00626158

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States

The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

Completed

Conditions: Cardiovascular Disease

First Posted Date: 2008-02-29

Last Posted Date: 2011-09-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 60

Registration Number: NCT00627068

Locations: 🇺🇸
UCSF, Department of Cardiology, San Francisco, California, United States

Nicotine Replacement and Counseling In Adolescents

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Drug: Nicotine nasal spray
Behavioral: Smoking cessation counseling

First Posted Date: 2008-02-28

Last Posted Date: 2008-02-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT00625794

Locations: 🇺🇸
UCSF, San Francisco, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy